Document Detail

Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
MedLine Citation:
PMID:  17536875     Owner:  NLM     Status:  MEDLINE    
Plasmodium falciparum infection during pregnancy is strongly associated with maternal anaemia and low birth weight, contributing to substantial morbidity and mortality in sub-Saharan Africa. Intermittent preventive treatment in pregnancy with sulfadoxine/pyrimethamine (IPTp-SP) has been one of the most effective approaches to reduce the burden of malaria during pregnancy in Africa. IPTp-SP is based on administering >or=2 treatment doses of sulfadoxine/pyrimethamine to pregnant women at predefined intervals after quickening (around 18-20 weeks). Randomised, controlled trials have demonstrated decreased rates of maternal anaemia and low birth weight with this approach. The WHO currently recommends IPTp-SP in malaria-endemic areas of sub-Saharan Africa. However, implementation has been suboptimal in part because of concerns of potential drug toxicities. This review evaluates the toxicity data of sulfadoxine/pyrimethamine, including severe cutaneous adverse reactions, teratogenicity and alterations in bilirubin metabolism. Weekly sulfadoxine/pyrimethamine prophylaxis is associated with rare but potentially fatal cutaneous reactions. Fortunately, sulfadoxine/pyrimethamine use in IPTp programmes in Africa, with 2-4 treatment doses over 6 months, has been well tolerated in multiple IPTp trials. However, sulfadoxine/pyrimethamine should not be administered concurrently with cotrimoxazole given their redundant mechanisms of action and synergistic worsening of adverse drug reactions. Therefore, HIV-infected pregnant women in malaria endemic areas who are already receiving cotrimoxazole prophylaxis should not also receive IPTp-SP. Although folate antagonist use in the first trimester is associated with neural tube defects, large case-control studies have demonstrated that sulfadoxine/pyrimethamine administered as IPTp (exclusively in the second and third trimesters and after organogenesis) does not result in an increased risk of teratogenesis. Folic acid supplementation is recommended for all pregnant women to reduce the rate of congenital anomalies but high doses of folic acid (5 mg/day) may interfere with the antimalarial efficacy of sulfadoxine/pyrimethamine. However, the recommended standard dose of folic acid supplementation (0.4 mg/day) does not affect antimalarial efficacy and may provide the optimal balance to prevent neural tube defects and maintain the effectiveness of IPTp-SP. No clinical association between sulfadoxine/pyrimethamine use and kernicterus has been reported despite the extensive use of sulfadoxine/pyrimethamine and related compounds to treat maternal malaria and congenital toxoplasmosis in near-term pregnant women and newborns. Although few drugs in pregnancy can be considered completely safe, sulfadoxine/pyrimethamine - when delivered as IPTp - has a favourable safety profile. Improved pharmacovigilance programmes throughout Africa are now needed to confirm its safety as access to IPTp-SP increases. Given the documented benefits of IPTp-SP in malaria endemic areas of Africa, access to this treatment for pregnant women should continue to expand.
Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Related Documents :
23045985 - Comparison of maternal abdominal subcutaneous fat thickness and body mass index as mark...
24833075 - Younger women with ovulation disorders and unexplained infertility predict a higher suc...
23460835 - Consumption of artificially-sweetened soft drinks in pregnancy and risk of child asthma...
24959475 - Small intestine ischaemia due to volvulus during pregnancy.
1837455 - Fetal abdominal wall defect: a new complication of vesicoamniotic shunting.
21427015 - Indices and detectors for fetal mcg actography.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drug safety     Volume:  30     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2007  
Date Detail:
Created Date:  2007-05-31     Completed Date:  2007-08-07     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  481-501     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Abnormalities, Drug-Induced
Antimalarials / administration & dosage,  adverse effects*,  pharmacology
Drug Administration Schedule
Drug Combinations
Drug Resistance
Infant, Newborn
Kernicterus / chemically induced
Malaria, Falciparum / prevention & control*
Plasmodium falciparum / drug effects
Pregnancy Complications, Parasitic / prevention & control*
Pyrimethamine / administration & dosage,  adverse effects*,  pharmacology
Sulfadoxine / administration & dosage,  adverse effects*,  pharmacology
Reg. No./Substance:
0/Antimalarials; 0/Drug Combinations; 37338-39-9/fanasil, pyrimethamine drug combination; 88463U4SM5/Sulfadoxine; Z3614QOX8W/Pyrimethamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of restricting paracetamol pack sizes on paracetamol poisoning in the United Kingdom: a revie...
Next Document:  Incidence and nature of medication errors in neonatal intensive care with strategies to improve safe...